ArticleTranslational stroke research2023
LncRNAs: Promising Therapeutic Targets and Biomarkers for Ischemic Stroke.
Article in Translational stroke research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Targeting Epigenetics in Ischemic Stroke: From Mechanisms to Therapeutics.Current neuropharmacology · 2026Review
- LINC00265 Serves as a Diagnostic and Prognostic Marker for Acute Ischemic Stroke and INHIBITS Disease Progression Through the miR- 155 - 5p/TRIM32 Axis.Molecular neurobiology · 2025Article
- Electroacupuncture Inhibits Ferroptosis by Modulating Iron Metabolism and Oxidative Stress to Alleviate Cerebral Ischemia-Reperfusion Injury.Journal of molecular neuroscience : MN · 2025Article
- Circulating PIWI-interacting RNAs in Acute Ischemic Stroke patients.Non-coding RNA research · 2025Article
- Multicenter Validation of lncRNA and Target mRNA Diagnostic and Prognostic Biomarkers of Acute Ischemic Stroke From Peripheral Blood Leukocytes.Journal of the American Heart Association · 2024Article
- Investigating the therapeutic potential of hesperidin targeting CRISP2 in intervertebral disc degeneration and cancer risk mitigation.Frontiers in pharmacology · 2024Article
- Glycerophosphoinositol modulates FGA and NOTCH3 in exercise-induced muscle adaptation and colon cancer progression.Frontiers in pharmacology · 2024Article
- Identification of circulating immune landscape in ischemic stroke based on bioinformatics methods.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Ischemic stroke is one of the leading causes of mortality and disability worldwide. Currently, options for ischemic stroke clinical therapy remain limited to intravenous thrombolysis and thrombectomy, which can only be applied to a minority of patients due to narrow therapeutic time window. Therefore, the discovery of new therapeutic targets and biomarkers is of great significance for ischemic stroke therapy. Long non-coding RNAs (lncRNAs) are the most extensive ncRNA transcripts and play critical roles in different kinds of diseases. Accumulative evidence suggests that lncRNAs are widely involved in multiple pathophysiological processes of ischemic stroke, highlighting their potential role as ischemic stroke therapeutic targets. Moreover, the significantly altered expression of lncRNAs in circulation of ischemic stroke patients reveals that they may serve as diagnostic, therapeutic, and prognosis biomarkers for ischemic stroke. In this commentary, we provide an overview of the roles of lncRNAs in the pathophysiology of ischemic stroke and discuss the opportunities of lncRNAs in the diagnosis and treatment of ischemic stroke. In addition, the challenges for the clinical translation of lncRNAs in ischemic stroke are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.